Medical device firm AtriCure has introduced new cryoFORM cryoablation probe, which has been designed to carry out a variety of surgical ablation procedures.
The new cryoFORM product is part of the cryoICE family of ablation products, which are used in the cryosurgical treatment of cardiac arrhythmias.
AtriCure president and CEO Mike Carrel said: "This builds off of one of our company’s core competencies in cryoablation, and offers our customers another option when performing surgical ablation by allowing for easier manipulation and application of the device.
"We have listened to our customers’ requests for a significantly more flexible probe that doesn’t compromise on the core strengths and features they value most."
Based on the firm’s cryoablation technology, the new product includes features such as thermal capacity to remove heat and active defrost that enables the probe to be safely and quickly detached while maintaining the tissue’s frozen state.
The firm has developed cryoFORM probe to deploy more minimally invasive techniques in cardiac surgery, which are being used in conjunction with a variety of cardiac therapies, including mitral and aortic valve repair.
The cryogen supply tubing of the cryoFORM probe helps in easier handling and delivery, enhancing the overall ease-of-use in settings where range of motion is limited.
According to the firm, the cryoFORM received CE mark approval and is awaiting FDA approval.
AtriCure also produces surgical device Synergy ablation system to treat persistent and longstanding persistent forms of atrial fibrillation (Afib) and AtriClip left atrial appendage management (LAAM) exclusion device for the occlusion of the left atrial appendage.